

# Matthew R Trendowski

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/960191/publications.pdf>

Version: 2024-02-01

25  
papers

552  
citations

758635

12  
h-index

713013

21  
g-index

25  
all docs

25  
docs citations

25  
times ranked

1037  
citing authors

#	ARTICLE	IF	CITATIONS
1	Chemotherapy-induced peripheral neuropathy in African American cancer survivors: Risk factors and quality of life outcomes. <i>Cancer Medicine</i> , 2021, 10, 8151-8161.	1.3	13
2	Generation and Quantitative Analysis of Pulsed Low Frequency Ultrasound to Determine the Sonic Sensitivity of Untreated and Treated Neoplastic Cells. <i>Journal of Visualized Experiments</i> , 2015, , e53060.	0.2	0
3	Effects of cytochalasin congeners, microtubule-directed agents, and doxorubicin alone or in combination against human ovarian carcinoma cell lines in vitro. <i>BMC Cancer</i> , 2015, 15, 632.	1.1	14
4	Using Cytochalasins to Improve Current Chemotherapeutic Approaches. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2015, 15, 327-335.	0.9	57
5	Using the Promise of Sonodynamic Therapy in the Clinical Setting against Disseminated Cancers. <i>Chemotherapy Research and Practice</i> , 2015, 2015, 1-16.	1.6	18
6	Chemotherapy in vivo against M109 murine lung carcinoma with cytochalasin B by localized, systemic, and liposomal administration. <i>Investigational New Drugs</i> , 2015, 33, 280-289.	1.2	17
7	The inherent metastasis of leukaemia and its exploitation by sonodynamic therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 149-163.	2.0	30
8	Chemotherapy with cytochalasin congeners in vitro and in vivo against murine models. <i>Investigational New Drugs</i> , 2015, 33, 290-299.	1.2	33
9	Effects of alkylation and immunopotentialization against Ehrlich ascites murine carcinoma in vivo using novel tetra-O-acetate haloacetamido carbohydrate analogs. <i>European Journal of Medicinal Chemistry</i> , 2015, 98, 149-159.	2.6	1
10	PU-H71: An improvement on nature's solutions to oncogenic Hsp90 addiction. <i>Pharmacological Research</i> , 2015, 99, 202-216.	3.1	32
11	Preferential enlargement of leukemia cells using cytoskeletal-directed agents and cell cycle growth control parameters to induce sensitivity to low frequency ultrasound. <i>Cancer Letters</i> , 2015, 360, 160-170.	3.2	16
12	Preparation, In Vivo Administration, Dose-Limiting Toxicities, and Antineoplastic Activity of Cytochalasin B. <i>Translational Oncology</i> , 2015, 8, 308-317.	1.7	7
13	Targeting the plasma membrane of neoplastic cells through alkylation: a novel approach to cancer chemotherapy. <i>Investigational New Drugs</i> , 2015, 33, 992-1001.	1.2	2
14	Effects of mTOR inhibitors and cytoskeletal-directed agents alone and in combination against normal and neoplastic hematopoietic cells in vitro. <i>Investigational New Drugs</i> , 2015, 33, 1162-1174.	1.2	3
15	Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products. <i>Drugs</i> , 2015, 75, 1993-2016.	4.9	51
16	Sonodynamic Therapy. , 2015, , 4281-4285.		0
17	Sonodynamic Therapy. , 2015, , 1-6.		0
18	Abstract 1640: Exploiting the cytoskeletal filaments of neoplastic cells to potentiate a novel therapeutic approach. <i>Cancer Research</i> , 2015, 75, 1640-1640.	0.4	1

#	ARTICLE	IF	CITATIONS
19	Enlargement and multinucleation of u937 leukemia and MCF7 breast carcinoma cells by antineoplastic agents to enhance sensitivity to low frequency ultrasound and to DNA-directed anticancer agents. <i>Anticancer Research</i> , 2015, 35, 65-76.	0.5	9
20	The rhetoric of cancer. <i>Cancer Causes and Control</i> , 2014, 25, 1243-1246.	0.8	1
21	The promise of sonodynamic therapy. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 143-160.	2.7	176
22	Exploiting the cytoskeletal filaments of neoplastic cells to potentiate a novel therapeutic approach. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 599-616.	3.3	38
23	The real deal: using cytochalasin B in sonodynamic therapy to preferentially damage leukemia cells. <i>Anticancer Research</i> , 2014, 34, 2195-202.	0.5	22
24	Tolerated doses in zebrafish of cytochalasins and jasplakinolide for comparison with tolerated doses in mice in the evaluation of pre-clinical activity of microfilament-directed agents in tumor model systems in vivo. <i>In Vivo</i> , 2014, 28, 1021-31.	0.6	11
25	Evaluation of health behaviors and overall quality of life in younger adult African American cancer survivors. <i>Cancer Medicine</i> , 0, , .	1.3	0